Medivand: Request for a clinical trial for a new product – the capital market

The Israeli Biotechnology Company

Medivand
+ 15.54%

closure:0

opening:0

High:0

low:0

cycle:–

Page Quote News Graphs Company Profile Recommendations


More articles on the subject:




Traded on the NASDAQ and held (35%) by

Clal Biotechno
-2.85%

Base:207.2

opening:206.7

High:207

low:200

change:781,064

Page Quote News Graphs Company Profile Recommendations


More articles on the subject:




Submission to the FDA for approval of a Phase I / II clinical trial of MWPC005 for the treatment of non-melanoma skin cancer patients The company is preparing for the opening of the trial in the United States in the second quarter of the year, while at the same time a Phase II “initiator-research” study will be conducted at Soroka Medical Center. Medivand expects data from both studies to be received by the end of 2021.

It is a dermatological biologic drug that is in the development stages and is based on the active ingredient of the two drugs it has already developed from Devand: NexoBrid for the treatment of burns and EscharEx for the treatment of chronic wounds and healing wounds. According to Medivand, a preclinical study combining existing scientific evidence with models of skin cancer suggests that the product may help treat low-risk, non-melanoma malignant skin tumors.

“Non-melanoma skin cancers, including basal cell carcinoma, are the most common of all cancers, and in this respect there is significant market potential,” he said. Sharon Malka, CEO of Divand. “We believe MWPC005 has the potential to be an effective, non-invasive treatment for basal cell carcinoma, with no side effects associated with currently existing skin care treatments or their long duration of treatment.”

Basal cell carcinoma (BCC) is a non-melanoma skin cancer that develops in the basal layers of the epidermis. According to the American Cancer Society, this is the most diagnosed skin cancer in the United States, with about 4.3 million diagnosed each year.